ClinicalTrials.gg
TerminatedNCT00105313Updated Jun 14, 2007

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

A Phase 1 interventional study of MEDI-507 in Lymphoma, Leukemia and Cancer, sponsored by MedImmune LLC. Terminated at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-06-14.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Why this study was terminated
After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Lymphoma by AstraZeneca — 3 open to participants now, 5 under way, 2 of them phase 3. Lymphoma · AstraZeneca.

Planned enrollment
8th of 20
80 · median 57
Started
2005
with 1 other
Phase 1
13 of 22
none open now
Registered
2nd of 22
by date

Among the 22 studies in Lymphoma by AstraZeneca, this one is the 8th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2005, is one of 13 in phase 1, and was the 2nd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

3 of the 22 studies in Lymphoma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Lymphoma by AstraZeneca, or all of them as a file.
02

Study summary

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507.

For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

03

Conditions studied

  • Lymphoma
  • Leukemia
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Individuals may be eligible for this study if they are 18 years of age or older and:

  • Have one of the following types of T-Cell Lymphoproliferative disorders such as Cutaneous T-cell Lymphoma (CTCL), Peripheral T-cell Lymphoma (PCTL), Large Cell Lymphoma (LGL), or Adult T-cell Lymphoma (ATL). Patients should have disease that is resistant or to the front-line therapy, except ATL patients for whom there is no standard therapy.
  • At least 30% of tumor cells must be CD2 positive.
  • Performance status of greater than or equal to 70% (able to care for themselves; but unable to carry on normal activity or to do active work).
  • At least 3 weeks must have passed since prior systemic cytotoxic chemotherapy, prolonged or cytolytic therapy or major surgery, and all treatment-related toxicities must have resolved prior to the first MEDI-507 administration (except thrombocytopenia).
  • Have no prior treatment with MEDI-507.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. To determine the maximum tolerated dose (MTD) or the optimal biological dose

  2. (OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with

  3. CD-2 positive lymphoproliferative disorders.

07

Study locations

11 sites
  • USC/Norris Cancer Center
    Los Angeles, California 90033, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • Georgetown University Medical Center, Lombardi Comprehensive Cancer Center
    Washington, District of Columbia 20007, United States
  • H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc
    Tampa, Florida 33612, United States
  • University of Maryland School of Medicine, Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Tufts New England Medical Center
    Boston, Massachusetts 02111, United States
  • Washington University
    St. Louis, Missouri 63110, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27517, United States
  • Kimmel Cancer Center, Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 14, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00105313
Lead sponsor
MedImmune LLC
First posted
Mar 14, 2005
Start date
Feb 2005
Last update
Jun 14, 2007

Study contacts

Luz Hammershaimb, MD
study director · MedImmune LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion